OptimizeRX (OPRX) Reiterated at Buy by Stifel as New AI Tool Launched

June 29, 2026 7:24 AM

Stifel analyst David Grossman reiterated a Buy rating and $14.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "This week ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found